To view this page ensure that Adobe Flash Player version 11.1.0 or greater is installed.
Francesco Bandello is Full Professor and Chairman of the Department of Ophthalmology, University Vita-Salute, Ospedale
San Raffaele of Milan and Academic Dean “Corso di Laurea Specialistica/Magistrale in Medicina e Chirurgia” at the University
Vita-Salute, Scientific Institute San Raffaele of Milan. Dr Bandello holds positions on many international societies, including
President of the European Society of Retina Specialists (EURETINA), President of Academia Ophthalmologica Europea, US
National Institutes of Health (NIH) peer reviewer for grant applications (since 2006) and Fellow of the European Leadership
Development Programme (EuLDP) of the American Academy of Ophthalmology. He is a former board member of the Club
Jules Gonin, Former Executive Committee Member of The Macula Society, former President of the Italian Society of the
Retina (SIR) and a past member of the International Executive Committee Michaelson Symposium, the Subcommittee for
Michaelson Award and the Scientific Advisory Board Panel of AMD Alliance International. He is also an executive board member of the European
School for Advanced Studies in Ophthalmology foundation (ESASO), a member of the Board of Directors of Retina Global and Committee Chair
of Vitreoretinal Diseases – Residency Curriculum of International Council of Ophthalmology (ICO). Dr Bandello is Co-Editor of the European
Journal of Ophthalmology, Associate Editor of Ophthalmologica and an editorial board member of many journals, including Ophthalmic Research,
Acta Diabetologica, European Ophthalmic Review and Retinal Physician. He is the co-author of nine books and has published 291 articles on
PubMed journals, mainly related to retinal diseases. Dr Bandello served as a trained principal investigator in several clinical trials performed
following International Conference of Harmonization/Good Clinical Practice (ICH/GCP) and mainly concerning age-related macular degeneration
and diabetic retinopathy.
A dvances in the understanding of the pathophysiology of diabetic macular oedema (DMO) have led to the widespread use of
corticosteroids and agents targeted against vascular endothelial growth factor (VEGF) in the treatment of DMO, and this forms the
focus of three articles in this edition of European Ophthalmic Review. My colleagues and I present an overview of the use of intravitreal
ranibizumab in DMO. Of particular interest is the recent PROTOCOL T clinical study that compares the efficacy and safety of three
anti-VEGF agents in DME: ranibizumab, bevacizumab and aflibercept. This study is also discussed in an article by Korobelnik and Wolf,
which reviews the use of intravitreal aflibercept in DMO. While anti-VEGF therapy has shown successful outcomes in DME, many consider
corticosteroids to be more beneficial in chronic DMO, when VEGF is no longer the primary driver of pathological changes in the eye.
An article by Quhill describes real-world experience of the fluocinolone acetonide intravitreal implant in DMO.
European Ophthalmic Review would like to take this opportunity to thank all participants on this edition. A special thanks goes to our
editorial board for their continuing support and invaluable guidance and the biggest thanks are reserved for the expert authors, who
spared precious time and effort to produce an interesting selection of articles. n
© To u ch MEd ica l MEdia